We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
0
0 active
Approvals
Total approvals
Agencies
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No approval data available
• The Noramco Group is investing $25 million in its Halo Pharma facility in Whippany, New Jersey to establish sterile injectable manufacturing capabilities, addressing critical capacity shortages in the US supply chain. • The expansion includes installation of a high-speed Groninger UFVN FlexFill filling line and SKAN isolator, with annual production capacity exceeding 50 million units for syringes, cartridges, and vials. • The new sterile manufacturing line is expected to be qualified and operational within 12 months, with facility upgrades meeting both US quality standards and EU Annex 1 compliance for European market access.
